Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

EGF-dependent induction of BCL-xL and p21CIP1/WAF1 is highly variable in HNSCC cells--implications for EGFR-targeted therapies.

Rüddel J, Wennekes VE, Meissner W, Werner JA, Mandic R.

Anticancer Res. 2010 Nov;30(11):4579-85.

PMID:
21115909
2.

Epidermal growth factor receptor-mediated proliferation of enterocytes requires p21waf1/cip1 expression.

Sheng G, Bernabe KQ, Guo J, Warner BW.

Gastroenterology. 2006 Jul;131(1):153-64.

PMID:
16831599
4.

1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1).

Muto A, Kizaki M, Yamato K, Kawai Y, Kamata-Matsushita M, Ueno H, Ohguchi M, Nishihara T, Koeffler HP, Ikeda Y.

Blood. 1999 Apr 1;93(7):2225-33.

5.

[Inhibition of curcumin on histone deacetylase and expression promotion of P21 (WAF1/CIP1) in HepG2 cells].

Lv BH, Zhang L, Zhu CC, Liu J.

Zhongguo Zhong Yao Za Zhi. 2007 Oct;32(19):2051-5. Chinese.

PMID:
18161303
6.

EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines.

Krohn V, Wiegand S, Werner JA, Mandic R.

Anticancer Res. 2011 Jan;31(1):59-65.

PMID:
21273581
7.
8.

Association of increased radiocurability of murine carcinomas with low constitutive expression of p21(WAF1/CIP1) protein.

Akimoto T, Seong J, Hunter NR, Buchmiller L, Mason K, Milas L.

Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):413-9.

PMID:
10760438
9.

Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells.

Wu Q, Kirschmeier P, Hockenberry T, Yang TY, Brassard DL, Wang L, McClanahan T, Black S, Rizzi G, Musco ML, Mirza A, Liu S.

J Biol Chem. 2002 Sep 27;277(39):36329-37. Epub 2002 Jul 22.

10.

Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.

Mandic R, Rodgarkia-Dara CJ, Krohn V, Wiegand S, Grénman R, Werner JA.

Anticancer Res. 2009 Apr;29(4):1181-7.

11.

Celecoxib toxicity is cell cycle phase specific.

Bock JM, Menon SG, Sinclair LL, Bedford NS, Goswami PC, Domann FE, Trask DK.

Cancer Res. 2007 Apr 15;67(8):3801-8.

12.

Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.

Yamashita H, Murakami N, Asari T, Okuma K, Ohtomo K, Nakagawa K.

Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1165-72. doi: 10.1016/j.ijrobp.2008.09.005. Epub 2008 Dec 26.

PMID:
19101092
13.

The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line.

Matsui TA, Sowa Y, Murata H, Takagi K, Nakanishi R, Aoki S, Yoshikawa M, Kobayashi M, Sakabe T, Kubo T, Sakai T.

Int J Oncol. 2007 Oct;31(4):915-22.

PMID:
17786325
14.

NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress.

Clark DW, Mitra A, Fillmore RA, Jiang WG, Samant RS, Fodstad O, Shevde LA.

Curr Cancer Drug Targets. 2008 Aug;8(5):421-30.

PMID:
18690848
15.

Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells.

Croucher DR, Rickwood D, Tactacan CM, Musgrove EA, Daly RJ.

Mol Cell Biol. 2010 Nov;30(21):5057-70. doi: 10.1128/MCB.00249-10. Epub 2010 Aug 30.

16.

Heregulin beta1 promotes breast cancer cell proliferation through Rac/ERK-dependent induction of cyclin D1 and p21Cip1.

Yang C, Klein EA, Assoian RK, Kazanietz MG.

Biochem J. 2008 Feb 15;410(1):167-75.

PMID:
17941827
18.

Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.

Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA, Dimitroulakos J.

J Cancer Res Clin Oncol. 2003 Nov;129(11):631-41. Epub 2003 Aug 26.

PMID:
12942316
19.
20.

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.

Supplemental Content

Support Center